Erin Leah Deery

Array ( [id] => 17792513 [patent_doc_number] => 20220251604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Oncolytic adenovirus and checkpoint inhibitor combination therapy [patent_app_type] => utility [patent_app_number] => 17/618932 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792111 [patent_doc_number] => 20220251202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION [patent_app_type] => utility [patent_app_number] => 17/616157 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20479414 [patent_doc_number] => 12527879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors [patent_app_type] => utility [patent_app_number] => 17/616002 [patent_app_country] => US [patent_app_date] => 2020-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 1144 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18309847 [patent_doc_number] => 20230113747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => IMMUNOGENIC PEPTIDES WITH AN OXIDOREDUCTASE MOTIF COMPRISING A MODIFIED CYSTEINE [patent_app_type] => utility [patent_app_number] => 17/611290 [patent_app_country] => US [patent_app_date] => 2020-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760030 [patent_doc_number] => 20220233642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => TREATMENT OF ARDS [patent_app_type] => utility [patent_app_number] => 17/610296 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492641 [patent_doc_number] => 12534504 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Il-2 mutant protein proliferating immune cells [patent_app_type] => utility [patent_app_number] => 17/610538 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 51 [patent_no_of_words] => 8063 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775025 [patent_doc_number] => 20220241374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS [patent_app_type] => utility [patent_app_number] => 17/611487 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17884036 [patent_doc_number] => 20220299513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => IRF2 AS A PROGNOSTIC BIOMARKER AND TARGET FOR AUGMENTING IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/608890 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704571 [patent_doc_number] => 20220204577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Synthetic Peptides With Affinity for the Interleukin-10 Receptor, Pharmaceutical Composition and Use Thereof as Immunomodulators for Treating Autoimmune, Inflammatory or Allergic Diseases [patent_app_type] => utility [patent_app_number] => 17/601658 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593571 [patent_doc_number] => 20220143144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => TREATMENT INVOLVING INTERLEUKIN-2 (IL2) AND INTERFERON (IFN) [patent_app_type] => utility [patent_app_number] => 17/442568 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685906 [patent_doc_number] => 20220193198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => Interleukin-2 Variants with Modified Biological Activity [patent_app_type] => utility [patent_app_number] => 17/599326 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672690 [patent_doc_number] => 20220185857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/442772 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687759 [patent_doc_number] => 20220195051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => Fc-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENT, IN PARTICULAR TO THE CNS [patent_app_type] => utility [patent_app_number] => 17/599921 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704627 [patent_doc_number] => 20220204633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => FC-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENTS, IN PARTICULAR TO THE CNS [patent_app_type] => utility [patent_app_number] => 17/599856 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611522 [patent_doc_number] => 20220153801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => CLEC9A-BASED CHIMERIC PROTEIN COMPLEXES [patent_app_type] => utility [patent_app_number] => 17/598573 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563219 [patent_doc_number] => 20220127368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => BISPECIFIC IMMUNOTOXINS TARGETING HUMAN CD25+CCR4+ TUMORS AND REGULATORY T-CELLS [patent_app_type] => utility [patent_app_number] => 17/431853 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8111 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503553 [patent_doc_number] => 20220096655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => PLASMA POLYMER NANOPARTICLES CARRYING AGENTS [patent_app_type] => utility [patent_app_number] => 17/429754 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458797 [patent_doc_number] => 20220072101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => HARNESSING INFLAMMATION TO TREAT NEURODEVELOPMENTAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/419870 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17291004 [patent_doc_number] => 20210386843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => mRNA Vaccine [patent_app_type] => utility [patent_app_number] => 17/420556 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034664 [patent_doc_number] => 20220378879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => APPLICATION OF PEG INTERFERON AND PROTOONCOGENE PRODUCT TARGETING INHIBITOR IN SYNERGISTIC TREATMENT OF RENAL CARCINOMA [patent_app_type] => utility [patent_app_number] => 17/754353 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754353 [rel_patent_id] =>[rel_patent_doc_number] =>)